Shares of MaxCyte, Inc. (LON:MXCT – Get Free Report) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 330.81 ($4.33) and traded as low as GBX 300 ($3.92). MaxCyte shares last traded at GBX 300 ($3.92), with a volume of 15,500 shares.
MaxCyte Trading Up 0.3 %
The stock has a 50-day moving average of GBX 330.71 and a 200 day moving average of GBX 336.23. The company has a quick ratio of 14.38, a current ratio of 14.31 and a debt-to-equity ratio of 8.37. The stock has a market cap of £315.27 million, a PE ratio of -1,153.85 and a beta of 1.13.
MaxCyte Company Profile
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
See Also
- Five stocks we like better than MaxCyte
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- How to Use the MarketBeat Excel Dividend Calculator
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Profitably Trade Stocks at 52-Week Highs
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
